Natalie S. Callander, MD, University of Wisconsin School of Medicine and Public Health

Articles

Influencing Factors to Initially Targeting BCMA in MM

February 1st 2021

Ongoing Approaches Toward Targeting BCMA

February 1st 2021

Next Steps for Use of Belantamab in Clinical Practice

February 1st 2021

DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

January 25th 2021

Management of Ocular Events From DREAMM-2 Regimen

January 25th 2021

DREAMM-2 Trial Regimen Safety Profile

January 18th 2021

DREAMM-2 Trial Efficacy Data and Recent FDA Approval

January 18th 2021

The Rationale for Targeting BCMA in Multiple Myeloma

December 18th 2020

Treatment Approach for R/R Multiple Myeloma

December 18th 2020

Future of BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

Bispecific Antibodies for Multiple Myeloma

July 17th 2020

Differentiating among CAR T Products for Multiple Myeloma

July 17th 2020

Development of CAR T Cells in Multiple Myeloma

July 17th 2020

Using Antibody-Drug Conjugates in Multiple Myeloma

July 17th 2020

BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

July 17th 2020

BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

July 17th 2020

Lenalidomide-Refractory Multiple Myeloma

July 17th 2020

Daratumumab With Carfilzomib in Frontline Multiple Myeloma

July 17th 2020

Management of Relapsed/Refractory Multiple Myeloma

July 17th 2020